SC6177

SC6177 is a preclinical-stage, first-in-class, brain-penetrant small molecule inhibitor of Group XV phospholipase A2 (PLA2G15), also known as lysosomal phospholipase A2. Developed by Scenic Biotech, SC6177 is designed to restore lysosomal function by preventing the degradation of bis(monoacylglycero)phosphate (BMP), a critical lysosomal lipid that supports waste-clearing enzymes. By elevating endogenous BMP levels, SC6177 aims to address lysosomal dysfunction, a core driver of neurodegeneration. The drug is being developed for the treatment of severe genetic and age-related neurodegenerative and neurometabolic disorders, including Batten disease, Niemann-Pick disease type C, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Scenic Biotech is conducting IND-enabling studies and plans to initiate first-in-human clinical trials in early 2027.